Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 231,958,512 papers from all fields of science
Search
Sign In
Create Free Account
LCZ 696
Known as:
LCZ-696
, LCZ696
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (3)
Aminobutyrates
Angiotensin Receptor Antagonists
Tetrazoles
Narrower (3)
Entresto
sacubitril
sacubitril / valsartan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.
C. Faselis
,
C. Boutari
,
M. Doumas
,
K. Imprialos
,
K. Stavropoulos
,
P. Kokkinos
Current pharmaceutical design
2017
Corpus ID: 3610687
Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits…
Expand
2017
2017
LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials)
Liwen Ye
,
Jian Wang
,
Qingwei Chen
,
Xixi Yang
OncoTarget
2017
Corpus ID: 29586574
Background To determine the effectiveness and safety of LCZ696 for the clinical treatment of hypertension, we performed a meta…
Expand
2017
2017
[Sacubitril/valsartan, a new and effective treatment for heart failure with reduced ejection fraction].
M. Senni
,
B. Trimarco
,
M. Emdin
,
L. De Biase
Giornale italiano di cardiologia
2017
Corpus ID: 25406835
Despite significant therapeutic advances, patients with chronic heart failure and reduced ejection fraction (HFrEF) remain at…
Expand
Review
2016
Review
2016
Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
G. Lippi
,
F. Sanchis-Gomar
International Journal of Cardiology
2016
Corpus ID: 24931364
Review
2016
Review
2016
Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
J. Vilela-Martin
Drug Design, Development and Therapy
2016
Corpus ID: 12314440
Heart failure is a global problem with elevated prevalence, and it is associated with substantial cardiovascular morbidity and…
Expand
2016
2016
Striking the Right Balance in Heart Failure
M. Shah
,
M. Lauer
Annals of Internal Medicine
2016
Corpus ID: 30932384
The treatment of heart failure with reduced ejection fraction (HFREF) is a fascinating story of our evolving understanding of how…
Expand
2015
2015
Efficacy of angiotensin–neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction
L. Ferrari
,
S. Sada
,
Gram
Internal and Emergency Medicine
2015
Corpus ID: 6424740
Angiotensin-converting enzyme (ACE) inhibitors are the cornerstone of the treatment for heart failure and a reduced ejection…
Expand
Review
2013
Review
2013
New drug therapies interfering with the renin–angiotensin–aldosterone system for resistant hypertension
M. Monge
,
A. Lorthioir
,
G. Bobrie
,
M. Azizi
Journal of the Renin-Angiotensin-Aldosterone…
2013
Corpus ID: 24297905
There is a persistent need for the development of new antihypertensive drugs, because the control of blood pressure is still not…
Expand
2013
2013
Abstract 456: Assessment of Pharmacokinetic Drug Interaction between LCZ696 and Metformin
Anisha E. Mendonza
,
M. Akahori
,
+4 authors
Priya Chandra
HYPERTENSION
2013
Corpus ID: 56842818
Objective: LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) being developed for the treatment of…
Expand
2010
2010
Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure
Z. Kobalava
,
E. Pavlikova
,
+5 authors
P. Jordaan
2010
Corpus ID: 57434174
Introduction: In the setting of heart failure (HF), chronic RAAS activation is detrimental, while NEP (neprilysin, NEP 24.11…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE